Interrupting ACE inhibitors and ARBs treatments in asymptomatic and stable patients with heart failure, kidney disease, diabetes or hypertension will disrupt clinical care and strongly require additional medical visits [111]. This evidence concerns the gene ACE and hypertensive disorder.